ValuEngine Upgrades Aethlon Medical (AEMD) to “Hold”

Aethlon Medical (NASDAQ:AEMD) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Monday, April 2nd.

AEMD stock traded up $0.07 during trading on Monday, hitting $1.39. 338,942 shares of the company’s stock traded hands, compared to its average volume of 484,656. The company has a debt-to-equity ratio of 0.18, a current ratio of 17.03 and a quick ratio of 17.03. Aethlon Medical has a 1 year low of $0.79 and a 1 year high of $3.85.

How to Become a New Pot Stock Millionaire

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.08 million. sell-side analysts expect that Aethlon Medical will post -0.48 EPS for the current year.

An institutional investor recently bought a new position in Aethlon Medical stock. Cordasco Financial Network purchased a new position in shares of Aethlon Medical (NASDAQ:AEMD) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 203,957 shares of the medical equipment provider’s stock, valued at approximately $230,000. Cordasco Financial Network owned about 1.35% of Aethlon Medical at the end of the most recent quarter. 5.14% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades Aethlon Medical (AEMD) to “Hold”” was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device for the single-use removal of life-threatening viruses from the circulatory system of infected individuals.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.

Leave a Reply